Gut Microbiome Profiling of Patients with Metastatic Breast Cancer Undergoing Immune Checkpoint Inhibitor Therapy

Conference Abstract
Written by Simran Padam

San Antonio Breast Cancer Symposium

View publication ↗

Simran Padam
Previous

Barriers to Participation in Therapeutic Clinical Trials as Perceived by Community Oncologists
Next

A Phase II Study of Pembrolizumab, Letrozole, and Palbociclib in Patients with Metastatic Estrogen Receptor-Positive Breast Cancer